CONGRESS HIGHLIGHTS

Highlights in myeloid malignancies

SUMMARY

Myeloid malignancies encompass a group of haematopoietic disorders including acute myeloid leukaemia (AML), myeloproliferative neoplasms, and myelodysplastic syndrome (MDS). At EHA 2024, the most recent updates in the area of myeloid malignancies were presented.

(BELG J HEMATOL 2024;15(5):205–10)

Highlights in acute lymphoblastic leukaemia

SUMMARY

The EHA 2024 congress was not only the opportunity to present updates on CAR-T cell therapy in the field of acute lymphoblastic leukaemia (ALL), but was also the occasion to present clinical updates on the use of blinatumomab in first-line treatment and important clinical studies for patients with Philadelphia-positive ALL. Below, we will discuss some of the key take-home messages from these sessions.

(BELG J HEMATOL 2024;15(5):201–4)

Highlights in myeloproliferative neoplasms

SUMMARY

The annual EHA meeting again featured several interesting oral abstracts and poster presentations in the field of myeloproliferative neoplasms (MPN). Below the highlights in Philadelphia positive (Ph+) chronic myeloid leukaemia (CML), Philadelphia negative MPN, polycythemia vera (PV) and myelofibrosis are summarised.

(BELG J HEMATOL 2024;15(5):197–200)

Highlights in lymphoma

SUMMARY

This report provides a summary of the most interesting presentations in the field of lymphoma at EHA 2024, including the use of glofitamab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), real-world data on the use of CAR-T cells in R/R DLBCL and several bispecific antibodies that could offer an important off-the-shelf treatment option for patients with heavily pre-treated relapsed/refractory follicular lymphoma.

(BELG J HEMATOL 2024;15(5):193–6)

Highlights in multiple myeloma

SUMMARY

During the last European Hematology Association (EHA) congress in Madrid, there were several presentations on the treatment of newly diagnosed and relapsed multiple myeloma. These included results from phase III trials, which will again change our treatment guidelines in the near future.

(BELG J HEMATOL 2024;15(5):190–2)

Highlights in chronic lymphocytic leukaemia

SUMMARY

At EHA 2024 new information on TP53 mutations in chronic lymphocytic leukemia (CLL) were presented together with preliminary or more mature data on doublets and triplets of novel agents. In the session on novel therapies in relapsed/refractory (R/R) CLL we were informed on the preliminary efficacy and safety of two BTK degraders (BGB-16673,NX-5948) and on the results of the bcl-2 inhibitor sonrotoclax in combination with zanubrutinib. Preliminary results on characteristics associated with response to lisocabtagene maraleucel (Liso-cel) in R/R CLL were also communicated.

(BELG J HEMATOL 2024;15(5):184–89)

VEXAS Syndrome: Current knowledge and management strategies

Described for the first time in 2020, VEXAS, an adult-onset ‘haemato-inflammatory syndrome’, is still largely unexplored. At the 2024 General Annual Meeting of the Belgian Hematology Society, Dr. Jérome Hadjadj (Hôpital Saint-Antoine, Paris, France) discussed the current understanding of this disease, covering its clinical manifestations, prognosis and potential treatments based on the knowledge available to date.